Alza Corp.'s president and chief operating officer, Jane Shaw,announced Tuesday at the Wheat First Securities Conference inNew York that the company's Testoderm system has beenapproved for marketing in Austria, France, Germany, Irelandand the United Kingdom.

The U.S. FDA approved the transdermal testosterone productfor hormonal replacement in hypogonadal males on Oct. 7.

Testoderm is the sixth transdermal product to be developed byAlza of Palo Alto, Calif. It's also the first product that thecompany (ASE:AZA) will market itself.

Alza's stock gained $2.25 a share on Tuesday, closing at $26.

(c) 1997 American Health Consultants. All rights reserved.